Company / FCF Margin
Entrada Therapeutics, Inc. FCF Margin History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-21.2%
FY2025
5-year range
-74.9% / 104.0%
FY2023-FY2025
Trend
-120.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from -74.9% to -21.2% over the past 2 years.
Based on SEC 10-K filings.
-21.2% in FY2025.
Improved from -74.9% to -21.2% over the past 2 years.
FCF Margin over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, fcf margin decreased 120.4% year-over-year.
Company context
Key Data Points
- Altman Z-Score -2.03 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -21.2% | -120.4% |
| FY2024 | 104.0% | +238.8% |
| FY2023 | -74.9% | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026